Could a blood pressure drug ease chest pain in people with clear arteries?
NCT ID NCT07670091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether bosentan, a drug that blocks a natural vessel-constricting substance, can improve blood flow in the tiny heart vessels of people with angina who have no major blockages. About 45 participants will get bosentan for 4 weeks and have MRI scans before and after. The goal is to understand if this approach could lead to new treatments for microvascular angina.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Bosentan (endothelin receptor antagonist)
- What this could lead to
- If it works, this could point toward a new treatment for angina caused by small vessel problems, not just blocked arteries.
- What could go wrong
- This is a very small, early study (45 people) looking at blood flow changes, not symptoms. Bosentan may not improve angina or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2023
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Clinical diagnosis of symptomatic angina, defined as the presence of substernal chest pain or discomfort provoked by exertion or emotional stress and relieved by rest and/or glyceryl trinitrate (nitroglycerin). 2. Age 18 years or older. 3. Able and willing to provide written informed consent. 4. Able and willing to adhere to study procedures and follow-up requirements. Exclusion Criteria: 1. Symptoms consistent with unstable angina, including: 2. Angina at rest lasting more than 20 minutes. 3. New-onset severe angina. 4. Angina increasing in frequency, duration, or occurring at a lower threshold. 5. Angina occurring following a recent myocardial infarction. 6. Known significant coronary artery disease, defined as previous investigations demonstrating greater than 50% epicardial coronary artery stenosis. 7. Uncontrolled hypertension, defined as clinic blood pressure greater than 140/90 mmHg despite treatment with three or more antihypertensive medications. 8. Pregnancy or breastfeeding. 9. Poorly controlled asthma as defined in the study protocol. 10. Severe heart failure or symptoms of active heart failure. 11. Significant chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m². 12. Clinical evidence of active infection at the time of recruitment. 13. Significant liver disease, defined as Child-Pugh Class B or C liver disease (or worse than Child-Pugh Class A). 14. Systolic blood pressure less than 90 mmHg at the time of recruitment. 15. Previously documented allergy or hypersensitivity to endothelin receptor antagonists. 16. Concurrent use of medications contraindicated with endothelin receptor antagonist therapy. 17. Requirement for invasive coronary angiography for another clinical indication, including but not limited to valvular heart disease assessment or intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Angina pectoris with normal coronary arteriogram are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NHS University Hospitals of Liverpool Group
Liverpool, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could High-Intensity workouts and diet tame chest pain from tiny heart vessels?
- Can an Hourglass-Shaped device relieve chest pain when arteries Aren't blocked?
- Microplastics in your blood: a hidden heart risk?
- Can a diabetes drug unclog the Heart's tiny vessels?
- Can a chinese herbal tablet help hearts heal after a heart attack?
- New hope for women with mysterious chest pain: tailored treatment on the horizon